Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, Phase 3a trial [published correction appears in
It can cause fatigue, weakness, constipation, loss of appetite, and weight loss
Animal studies have documented potential developmental effects at high doses, which led the FDA to assign a Category C classificationa label indicating caution rather than proven danger in humans
Side Effects These medications often cause nausea, vomiting, diarrhoea, or constipation
Thus, kidney-derived GPX3 can be transported to other tissues and bound to the basement membrane
and le Roux, C.W